Surely, one of the most well-known and clinically validated markers of prostate cancer is the prostate-specific membrane antigen (PSMA, also known as folate-hydrolase 1), a 100 kD transmembrane glycoprotein with expression properties that allow its use as diagnostic and therapeutic target (Figure 2) [57]. This evidence concerns the gene FOLH1 and prostate carcinoma.